{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T11:39:44Z","timestamp":1649158784564},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2014,11,6]],"date-time":"2014-11-06T00:00:00Z","timestamp":1415232000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1007\/s00280-014-2620-8","type":"journal-article","created":{"date-parts":[[2014,11,5]],"date-time":"2014-11-05T08:59:53Z","timestamp":1415177993000},"page":"1321-1324","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Safety and pharmacokinetics of S-1 in a recurrent colon cancer patient with chronic myeloid leukemia treated with dasatinib: a case report"],"prefix":"10.1007","volume":"74","author":[{"given":"Toshinori","family":"Sueda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiro","family":"Kudo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mamoru","family":"Uemura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junichi","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taishi","family":"Hata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ichiro","family":"Takemasa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsunekazu","family":"Mizushima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirofumi","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sachiko","family":"Ezoe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kana","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichiro","family":"Doki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taroh","family":"Satoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,11,6]]},"reference":[{"key":"2620_CR1","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3322\/caac.20073","volume":"60","author":"A Jemal","year":"2010","unstructured":"Jemal A, Siegel R, Xu J et al (2010) Cancer statistics. CA Cancer J Clin 60:277\u2013300","journal-title":"CA Cancer J Clin"},{"key":"2620_CR2","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1002\/cncr.24760","volume":"116","author":"BK Edwards","year":"2010","unstructured":"Edwards BK, Ward E, Kohler BA et al (2010) Report to the nation on the status of cancer, 1975\u20132006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer 116:544\u2013573","journal-title":"Cancer"},{"key":"2620_CR3","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1200\/JCO.2004.09.046","volume":"22","author":"RM Goldberg","year":"2004","unstructured":"Goldberg RM, Sargent DJ, Morton RF et al (2004) A randomized controlled trial of fl uorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23\u201330","journal-title":"J Clin Oncol"},{"key":"2620_CR4","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1200\/JCO.2004.05.113","volume":"22","author":"C Tournigand","year":"2004","unstructured":"Tournigand C, Andre T, Achille E et al (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22:229\u2013237","journal-title":"J Clin Oncol"},{"key":"2620_CR5","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/jjco\/hyn127","volume":"39","author":"T Shirasaka","year":"2009","unstructured":"Shirasaka T (2009) Development history and concept of an oral anticancer agent S-1 (TS-1): its clinical usefulness and future vistas. Jpn J Clin Oncol 39:2\u201315","journal-title":"Jpn J Clin Oncol"},{"key":"2620_CR6","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S1470-2045(10)70181-9","volume":"11","author":"K Muro","year":"2010","unstructured":"Muro K, Boku N, Shimada Y et al (2010) Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2\/3 non-inferiority study (FIRIS study). Lancet Oncol 11:853\u2013860","journal-title":"Lancet Oncol"},{"key":"2620_CR7","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S1470-2045(13)70490-X","volume":"14","author":"Y Yamada","year":"2013","unstructured":"Yamada Y, Takahari D, Matsumoto H et al (2013) Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial. Lancet Oncol 14:1278\u20131286","journal-title":"Lancet Oncol"},{"key":"2620_CR8","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1038\/sj.bjc.6604271","volume":"98","author":"Y Yamada","year":"2008","unstructured":"Yamada Y, Tahara M, Miya T et al (2008) Phase I\/II study of oxaliplatin with oral S-1 as first-line therapy for patients with metastatic colorectal cancer. Br J Cancer 98:1034\u20131038","journal-title":"Br J Cancer"},{"key":"2620_CR9","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1093\/annonc\/mds236","volume":"23","author":"HJ Schmoll","year":"2012","unstructured":"Schmoll HJ, Van Cutsem E, Stein A et al (2012) ESMO Consensus guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol 23:2479\u20132516","journal-title":"Ann Oncol"},{"key":"2620_CR10","unstructured":"Benson AB, Venook AP, Bekaii-Saab T et al\u00a0(2014) Colon cancer, version 3.2014: featured updates to the NCCN guidelines. J Natl Compr Canc Netw 12(7):1028\u20131059"},{"key":"2620_CR11","first-page":"2000","volume":"5","author":"K Hirata","year":"1999","unstructured":"Hirata K, Horikoshi N, Aiba K et al (1999) Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug. Clin Cancer Res 5:2000\u20132005","journal-title":"Clin Cancer Res"},{"key":"2620_CR12","first-page":"6956","volume":"48","author":"CJ Groeningen Van","year":"1988","unstructured":"Van Groeningen CJ, Pinedo HM, Heddrs J et al (1988) Pharmaco-kinetics of 5-fluorouracil assessed with a sensitive mass spectrometric method in patients on a dose escalation schedule. Cancer Res 48:6956\u20136961","journal-title":"Cancer Res"},{"issue":"21","key":"2620_CR13","doi-asserted-by":"crossref","first-page":"3432","DOI":"10.1182\/blood.V116.21.3432.3432","volume":"116","author":"P Rousselot","year":"2010","unstructured":"Rousselot P, Boucher S, Etienne G et al (2010) Pharmacokinetics of dasatinib as a first line therapy in newly diagnosed CML patients (OPTIM dasatinib trial): correlation with safety and response. Blood 116(21):3432","journal-title":"Blood"},{"key":"2620_CR14","first-page":"205","volume":"102","author":"S Takahashi","year":"2011","unstructured":"Takahashi S, Miyazaki M, Okamoto I et al (2011) Phase I study of dasatinib (BMS- 354825) in Japanese patients with solid tumors. Cancer Sci 102:205\u20132064","journal-title":"Cancer Sci"},{"issue":"2","key":"2620_CR15","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1054\/bjoc.2000.1236","volume":"83","author":"A Ohtsu","year":"2000","unstructured":"Ohtsu A, Baba H, Sakata Y et al (2000) Phase II study of S-1, a novel oral fluoropyrimidine derivative, in patients with metastatic colorectal carcinoma. Br J Cancer 83(2):141\u2013145","journal-title":"Br J Cancer"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-014-2620-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-014-2620-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-014-2620-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,26]],"date-time":"2020-08-26T13:19:25Z","timestamp":1598447965000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-014-2620-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,6]]},"references-count":15,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["2620"],"URL":"https:\/\/doi.org\/10.1007\/s00280-014-2620-8","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,6]]}}}